2025-2032 Published On : 05-06-2025
• As of 2023, the global Fatty Liver Drugs Market is valued at approximately USD 20.14 billion and is projected to reach USD 31.78 billion by 2032, reflecting a compound annual growth rate (CAGR) of 5.20% over the forecast period. This growth is fueled by increasing awareness, technological advancement in diagnostics, rising incidence of obesity, sedentary lifestyle, and growing investments in drug development for liverrelated conditions.
Email:
• One of the main factors propelling the market for fatty liver drug is the sharp increase in obesity, type 2 diabetes, and metabolic syndrome. These illnesses are significant risk factors for both NASH and NAFLD. In 2023, more than 1.9 billion adults were overweight, and more than 650 million were obese, according to the World Health Organization (WHO). A growing patient base is fueled by this upward trend, which also increases the need for efficient therapeutic solutions and promotes pharmaceutical investment.
Email:
•Vitamin E & Pioglitazone
•Obeticholic Acid •Elafibranor •Selonsertib
•Cenicriviroc
